The pathophysiology of CRS is associated with the overexpression of cytokines, including IL-6, TNF-α, IFNγ and IL-1, in a patient’s serum; so, blocking these cytokines can achieve the reversal of adverse events in CAR-T cell therapy against HNSCC [106]. The gene discussed is IFNG; the disease is congenital rubella syndrome.